Patents by Inventor Henrik MÖBITZ
Henrik MÖBITZ has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11878973Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.Type: GrantFiled: May 25, 2022Date of Patent: January 23, 2024Assignee: NOVARTIS AGInventors: Vincent Bordas, Jvan Brun, Markus Furegati, Jacques Hamon, Jürgen Hans-Hermann Hinrichs, Philipp Holzer, Fatma Limam, Henrik Möbitz, Sandro Nocito, Simone Plattner, Niko Schmiedeberg, Joseph Schoepfer, Ross Sinclair Strang, Frédéric Zecri
-
Publication number: 20230046859Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.Type: ApplicationFiled: May 25, 2022Publication date: February 16, 2023Inventors: Vincent BORDAS, Jvan BRUN, Andrea DECKER, Markus FUREGATI, Geoffrey GOGNIAT, Wanben GONG, Jacques HAMON, Jürgen Hans-Hermann HINRICHS, Philipp HOLZER, Fatma LIMAM, Henrik MÖBITZ, Sandro NOCITO, Simone PLATTNER, Niko SCHMIEDEBERG, Joseph SCHOEPFER, Jessica SOTO, Ross Sinclair STRANG, Shuping YAO, Huangchao YU, Frédéric ZECRI, Sisi ZHANG
-
Patent number: 10011599Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: GrantFiled: March 16, 2017Date of Patent: July 3, 2018Assignee: Novartis AGInventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
-
Patent number: 9840498Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.Type: GrantFiled: July 24, 2014Date of Patent: December 12, 2017Assignee: Novartis AGInventors: Zhenxing Du, Samuel Hintermann, Konstanze Hurth, Sébastien Jacquier, Hansjoerg Lehmann, Henrik Moebitz, Nicolas Soldermann, Aleksandar Stojanovic
-
Patent number: 9763952Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: GrantFiled: December 21, 2015Date of Patent: September 19, 2017Assignee: NOVARTIS AGInventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
-
Publication number: 20170183348Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: ApplicationFiled: March 16, 2017Publication date: June 29, 2017Inventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar Panigrahi, Ramulu PODDUTOORI, Susanta SAMAJDAR
-
Patent number: 9629836Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: GrantFiled: November 13, 2015Date of Patent: April 25, 2017Assignee: NOVARTIS AGInventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
-
Patent number: 9539260Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: GrantFiled: December 20, 2012Date of Patent: January 10, 2017Assignee: NOVARTIS AGInventors: Giorgio Caravatti, Sylvie Chamoin, Pascal Furet, Klemens Hogenauer, Konstanze Hurth, Karen Kammertoens, Ian Lewis, Henrik Moebitz, Alexander Baxter Smith, Nicolas Soldermann, Romain Wolf, Frederic Zecri
-
Publication number: 20160168131Abstract: Provided are substituted quinazolin-4-one compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein R1, R2, R3, R5, R6 and L are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the class I PI3K kinases.Type: ApplicationFiled: July 24, 2014Publication date: June 16, 2016Applicant: NOVARTIS AGInventors: Zhenxing DU, Samuel HINTERMANN, Konstanze HURTH, Sébastien JACQUIER, Hansjoerg LEHMANN, Henrik MOEBITZ, Nicolas SOLDERMANN, Aleksandar STOJANOVIC
-
Publication number: 20160136150Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: ApplicationFiled: November 13, 2015Publication date: May 19, 2016Applicant: NOVARTIS AGInventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar PANIGRAHI, Ramulu PODDUTOORI, Susanta SAMAJDAR
-
Publication number: 20160106753Abstract: The invention relates to dihydro-benzo-oxazine and dihydro-pyrido-oxazine compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, V, W, U, Q, R1, R5, R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: December 21, 2015Publication date: April 21, 2016Applicant: Novartis AGInventors: Giorgio CARAVATTI, Sylvie CHAMOIN, Pascal FURET, Klemens HOGENAUER, Konstanze HURTH, Christoph KALIS, Karen KAMMERTOENS, Ian LEWIS, Henrik MOEBITZ, Alexander Baxter SMITH, Nicolas SOLDERMANN, Romain WOLF, Frederic ZECRI
-
Patent number: 9227969Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: GrantFiled: August 5, 2014Date of Patent: January 5, 2016Assignee: NOVARTIS AGInventors: Mark Gary Bock, Henrik Moebitz, Sunil Kumar Panigrahi, Ramulu Poddutoori, Susanta Samajdar
-
Publication number: 20150148377Abstract: The invention relates to quinoline compounds of the formula (I) and/or pharmaceutically acceptable salts and/or solvates thereof, wherein Y, W, U, Q, R1, R5 R7 and R30 are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.Type: ApplicationFiled: December 20, 2012Publication date: May 28, 2015Applicant: NOVARTIS AGInventors: Klemens Hogenauer, Konstanze Hurth, Christoph Kalis, Henrik Moebitz, Nicolas Soldermann, Frederic Zecri
-
Publication number: 20150051209Abstract: The present invention relates to compounds of formula I: in which n, R1, R2, R3a, R4 and R5 are defined in the Summary of the Invention; capable of inhibiting the activity of MEK. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of hyperproliferative diseases like cancer.Type: ApplicationFiled: August 5, 2014Publication date: February 19, 2015Applicant: NOVARTIS AGInventors: Mark Gary BOCK, Henrik MOEBITZ, Sunil Kumar PANIGRAHI, Ramulu PODDUTOORI, Susanta SAMAJDAR
-
Patent number: 8946260Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.Type: GrantFiled: September 14, 2011Date of Patent: February 3, 2015Assignee: Novartis AGInventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
-
Publication number: 20150018338Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.Type: ApplicationFiled: July 7, 2014Publication date: January 15, 2015Applicant: NOVARTIS AGInventors: Sangamesh BADIGER, Murali CHEBROLU, Mathias FREDERIKSEN, Philipp HOLZER, Konstanze HURTH, Rainer Martin LEUOEND, Rainer MACHAUER, Henrik MOEBITZ, Ulf NEUMANN, Rita RAMOS, Henrich RUEEGER, Michael SCHAEFER, Marina TINTELNOT-BLOMLEY, Siem Jacob VEENSTRA, Markus VOEGTLE
-
Publication number: 20140045872Abstract: The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.Type: ApplicationFiled: September 14, 2011Publication date: February 13, 2014Applicant: NOVARTIS AGInventors: Mark Gary Bock, Christoph Gaul, Venkateshwar Rao Gummadi, Henrik Moebitz, Saumitra Sengupta
-
Patent number: 8614239Abstract: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds have been demonstrated as inhibitors of MEK and therefore may be useful in the treatment of hyperproliferative diseases (e.g., cancer and inflammation).Type: GrantFiled: December 7, 2010Date of Patent: December 24, 2013Assignee: Novartis AGInventors: Dinesh Chikkanna, Mark Gary Bock, Clive McCarthy, Henrik Moebitz, Chetan Pandit, Ramulu Poddutorri
-
Patent number: 8466289Abstract: The present invention relates to compounds of Formula I where R1a, R1b, X, R2a, R2b, W, R3, R4, and R5 are as defined herein as well as pharmaceutically acceptable salts thereof. The compounds have been shown to act as MEK inhibitors which may be useful in the treatment of hyperproliferative diseases, like cancer and inflammation.Type: GrantFiled: November 3, 2010Date of Patent: June 18, 2013Assignee: Novartis AGInventors: Mark G. Bock, Dinesh Chikkanna, Clive McCarthy, Henrik Moebitz, Chetan Pandit
-
Publication number: 20120302558Abstract: The invention relates to novel heterocyclic compounds of the formula in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.Type: ApplicationFiled: July 13, 2011Publication date: November 29, 2012Inventors: Sangamesh Badiger, Murali Chebrolu, Mathias Frederiksen, Philipp Holzer, Konstanze Hurth, Rainer Martin Lueoend, Rainer Machauer, Henrik Moebitz, Ulf Neumann, Rita Ramos, Heinrich Rueeger, Michael Schaefer, Marina Tintelnot-Blomley, Siem Jacob Veenstra, Markus Voegtle, Lei Li, Hui Liu, Xin Xiong